Myocardial infarction induced by ischemia/reperfusion (I/R) injury is a major clinical problem. During I/R injury, damage to the endothelial barrier allows a leakage of coagulation factors into the myocardium. Tissue factor (TF), the primary activator of the coagulation cascade, is constitutively expressed in the heart. Activation of coagulation cascade by TF has been shown to play a role in myocardial infarction after I/R injury. However, the role TF:FVIIa signaling has not been investigated. The TF:FVIIa complex can activate cells by cleavage of protease activated receptor-2 (PAR-2). Both TF and PAR-2 are expressed on cardiomyocytes as well as neutrophils, which infiltrate into the myocardium after I/R injury. My preliminary data demonstrate that PAR-2 deficiency results in significant reduction of infarct size, heart remodeling and heart dysfunction after I/R injury. In this proposal I hypothesize that TF:FVIIa- dependent activation of PAR-2 on both neutrophils and cardiomyocytes contributes to myocardial infarction and heart remodeling. The proposal has two specific aims.
In Specific Aim 1 I will investigate the role of TF:FVIIa-dependent activation of PAR-2 in infarct size using an in vivo mouse model of short-term I/R injury.
In Specific Aim 2 I will determine how TF:FVIIa-PAR-2 pathway contributes to heart remodeling after long- term I/R injury. In my proposal I will use unique set of tools that allow me to distinguish between signaling and coagulation properties of TF:FVIIa complex. Understanding the role of TF:FVIIa-dependent activation of PAR-2 in injured heart may lead to the development of new therapies to reduce myocardial infarction and heart failure.
A heart attack, also called myocardial infarction, results in heart muscle damage and with time may lead to the heart failure. Reducing the size of the initial infarct decreases the chance of developing heart failure. Our data indicates that deficiency of protease activated receptor-2 (PAR-2) reduces initial infarct size, attenuates heart remodeling and improves heart function in mouse models of cardiac ischemia/reperfusion injury. Therefore, blocking PAR-2-dependent signaling may be a new strategy to prevent heart muscle damage after a heart attack and consequently reducing the chance of developing heart failure.
|Pawlinski, Rafal (2014) Inhibit the calpain to climb the mountain. Blood 123:1123-4|
|Sparkenbaugh, Erica M; Chantrathammachart, Pichika; Mickelson, Jacqueline et al. (2014) Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123:1747-56|
|Magnus, Nathalie; Garnier, Delphine; Meehan, Brian et al. (2014) Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci U S A 111:3544-9|
|Antoniak, Silvio; Sparkenbaugh, Erica; Pawlinski, Rafal (2014) Tissue factor, protease activated receptors and pathologic heart remodelling. Thromb Haemost 112:893-900|
|Xu, Yongmei; Cai, Chao; Chandarajoti, Kasemsiri et al. (2014) Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. Nat Chem Biol 10:248-50|
|Chandarajoti, Kasemsiri; Xu, Yongmei; Sparkenbaugh, Erica et al. (2014) De novo synthesis of a narrow size distribution low-molecular-weight heparin. Glycobiology 24:476-86|
|Sparkenbaugh, Erica; Pawlinski, Rafal (2013) Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 162:3-14|
|Chantrathammachart, Pichika; Pawlinski, Rafal (2012) Tissue factor and thrombin in sickle cell anemia. Thromb Res 129 Suppl 2:S70-2|
|Pawlinski, Rafal; Holinstat, Michael (2011) We can do it together: PAR1/PAR2 heterodimer signaling in VSMCs. Arterioscler Thromb Vasc Biol 31:2775-6|